USPSTF advises against widespread prostate cancer screening
May 8, 2018|Internal Medicine
FROM JAMA
The evidence review was limited by several factors including a lack of data on newer treatments such as cryotherapy and high-intensity focused ultrasound, the researchers noted.
However, the data support an individualized approach to PSA screening for prostate cancer, in which each man can weigh the potential risks and benefits of screening, according to the USPSTF.
The research was funded by the Agency for Healthcare Research and Quality. The researchers had no financial conflicts to disclose.
SOURCE: Fenton J et al. JAMA. 2018;319(18):1914-31. and JAMA. 2018;319(18):1901-13.
